---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Phase of product development"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Phase of product development. Topics: Investigational status and current development phase; Regulatory status: Submission planned; U.S. and EU filings planned on ARCHER II results, timing not announced; FDA and EMA alignment on a global registration path; FDA alignment on best-corrected visual acuity loss as the primary outcome measure; 7 further topics. 11 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Investigational status and current development phase

> “The global, sham-controlled, double-masked Phase 3 ARCHER II trial is ongoing in 659 patients with GA.”
> “We do not have any products approved for sale, and we have not generated any revenue from product sales.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Submission planned; U.S. and EU filings planned on ARCHER II results, timing not announced

> “ARCHER II is a single protocol supporting a global registration path. The Phase 3 single study will be analyzed for EU filing and will be allocated into two pre-defined sub-studies for the U.S. filing and maintains strong statistical power at the sub-study level.”
> “An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026. If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027. Alternatively, the DMC may recommend continuing the trial through the Month 24 primary endpoint analysis. ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-2.1.1-3"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

### FDA and EMA alignment on a global registration path

> “We have established a global registration path with the FDA and EMA, which supports the potential of vonaprument to be the first treatment approved in both Europe and the U.S. for the protection of vision in patients with GA. The ARCHER II single overall study will be analyzed for EU registration and allocated into two pre-defined sub-studies that will be analyzed for U.S. registration in accordance with the FDA’s two-trial recommendation.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-5"></a>

### FDA alignment on best-corrected visual acuity loss as the primary outcome measure

> “Annexon has gained alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 registration program that includes using, for the first-time, the prevention of ≥15-letter loss of best corrected visual acuity (BCVA) as the primary outcome measure, as well as conducting a comparison of ANX007 to an injection agent, consistent with requests for trials across ophthalmic indications.”
> “Notably, the FDA has not required Annexon to study the slowing of lesion growth as measured by fundus autofluorescence (FAF), an anatomical endpoint used for the approval of other GA programs.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.1-6"></a>

### FDA Fast Track designation for geographic atrophy

> “The U.S. Food and Drug Administration (FDA) granted Fast Track designation to ANX007, an investigational antibody antigen-binding-fragment (Fab), for the treatment of geographic atrophy (GA).”

Source: [Annexon Biosciences second-quarter 2022 results press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-highlights-business-and-portfolio-progress)

> “The FDA has granted Fast Track designation for tanruprubart in GBS and for vonaprument in GA, and the EMA has granted PRIME designation for vonaprument in GA, and, in the future, we may seek Fast Track designation or PRIME designation for our product candidates.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-7"></a>

### EMA Priority Medicine (PRIME) designation

> “today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “The EMA granted this designation, which provides enhanced development support for priority medicines that target an unmet need, based on the Phase 2 ARCHER trial data that showed a statistically significant, durable, and dose-dependent preservation of visual function in patients with GA, as well as preclinical data supporting the protective effect of ANX007 against photoreceptor damage.”

Source: [Annexon Biosciences PRIME press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-receives-prime-designation-ema-anx007-treatment)

<a id="topic-2.1.1-8"></a>

### EMA Product Development Coordinator pilot

> “today announced that the European Medicines Agency (EMA) has selected vonaprument (formerly ANX007) to participate in the Product Development Coordinator (PDC) pilot.”
> “The PDC pilot was launched by the EMA in July 2025 to strengthen stewardship through development support activities. With background and expertise in the therapeutic area of the product, the PDC is charged with helping PRIME designation holders efficiently navigate through various regulatory interactions, including expedited scientific advice, marketing authorization application (MAA) submission readiness activities and ad-hoc queries throughout the development program.”

Source: [Annexon Biosciences PDC pilot press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-selected-ema-participate-product-development-coordinator)

<a id="topic-2.1.1-9"></a>

### Month 24 dual primary endpoint and open-label extension added in August 2026

> “today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).”
> “With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-2.1.1-10"></a>

### Regulatory risk stated by the sponsor for the amended design

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”
> “there is no assurance that either timepoint will show a statistically significant treatment effect, that the FDA, EMA or other regulators will agree that success at one timepoint is sufficient to support approval, or that the design amendment itself will not require additional discussion, data or time to align with regulators.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-11"></a>

### ARROW head-to-head trial against pegcetacoplan: planned in 2023

> “ARROW Head-to-Head Trial: The Phase 3 ARROW trial is designed to enroll approximately 500 patients with GA to evaluate a monthly dose of ANX007 versus SYFOVRE® as an injection comparator, an FDA-approved drug shown to slow lesion growth.”
> “ARCHER II is expected to begin enrollment in mid-2024, followed by ARROW in late 2024.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.1-12"></a>

### ARROW head-to-head trial against pegcetacoplan: no longer planned as of March 2025

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation. The primary endpoint of ARCHER II is prevention of ≥15-letter loss of BCVA, and an objective secondary structural measure is prevention of ellipsoid zone loss, both of which measures were met in the Phase 2 ARCHER trial. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”

Source: [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
